Description
The DoW Neurofibromatosis Investigator-Initiated Research Award supports high-impact research that addresses a critical need and has the potential to make important contributions to the field of neurofibromatosis disorders or advance patient care. The award mechanism offers two funding levels based on participation in two optional features: the Open Science Initiative and the Optional Qualified Collaborator. Research projects may focus on any phase of research, excluding clinical trials. The rationale for a research idea may be derived from laboratory discovery, population-based studies, a clinician’s firsthand knowledge of patients, or anecdotal data. Applications must include preliminary and/or published data that are relevant to NF and the proposed research project. Some key areas of emphasis for this award include NF2- and schwannomatosis-related areas, endpoint validation, biomarker discovery, and technological innovation.
• NF2- and schwannomatosis-related areas
• Endpoint validation, biomarker discovery, and technological innovation
• Application of data science
• Non-tumor manifestations
• Heterogeneity of NF-related phenotypes
• Genetics, genomics, epigenetics, systems biology, metabolomics, or similar approaches
• Preclinical efficacy studies
• Target identification and drug discovery
• Nutritional, environmental, and other modifiers of NF
• Health services research